Streetbeat News

Price Targets

GKOS

Truist Securities analyst Samuel Brodovsky has reiterated a Buy rating on Glaukos Corporation (NYSE:GKOS) and maintained a price target of $100.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 1:04 pm

ACAD

Analysts have provided varying ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) over the last quarter, with a total of 13 ratings ranging from bullish to bearish. The average 12-month price target for ACAD is $34.08, with a high estimate of $42.00 and a low estimate of $25.00, marking a 13.15% increase from the previous average of $30.12. Several analysts have raised their price targets and ratings, indicating a positive outlook on the company's performance. ACADIA Pharmaceuticals is a biotech company focusing on CNS disorders and has shown a revenue growth rate of 61.96% as of September 30, 2023, but with a net margin of -30.79% and an ROA of -10.22%. The company's market capitalization is below the industry average, and it has a debt-to-equity ratio of 0.16.

Portfolio Pulse from Benzinga Insights

December 29, 2023 | 1:00 pm

COP

Eight analysts have recently updated their ratings on ConocoPhillips (NYSE:COP), with a mix of bullish and neutral stances. The average 12-month price target is $140.38, with a high of $152.00 and a low of $125.00, marking a 1.75% decrease in the average target. Analysts from firms like Raymond James, UBS, JP Morgan, RBC Capital, Susquehanna, Jefferies, and Morgan Stanley have adjusted their ratings and price targets. ConocoPhillips is a major oil and gas producer with strong financial indicators such as a high net margin and ROE, but it has experienced a significant revenue decline in the last quarter.

Portfolio Pulse from Benzinga Insights

December 29, 2023 | 1:00 pm

ATUS

Benchmark analyst Matthew Harrigan has maintained a Buy rating on Altice USA (NYSE:ATUS) but has reduced the price target from $10 to $5.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 12:52 pm

TYRA

Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Tyra Biosciences (NASDAQ:TYRA) and maintained a price target of $27.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 12:45 pm

BSX

BTIG analyst Marie Thibault has reiterated a Buy rating on Boston Scientific (NYSE:BSX) and maintained a price target of $64.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 12:43 pm

HPP

BTIG analyst Thomas Catherwood has maintained a Buy rating on Hudson Pacific Properties (NYSE:HPP) and increased the price target from $11 to $13.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 12:39 pm

COP

Raymond James analyst John Freeman has maintained a Strong Buy rating on ConocoPhillips (NYSE:COP) but has reduced the price target from $146 to $140.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 12:36 pm

NEO

BTIG analyst Mark Massaro has maintained a Buy rating on NeoGenomics (NASDAQ:NEO) but has reduced the price target from $25 to $21. This adjustment reflects a more conservative valuation of the company's future prospects.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 12:19 pm

NTRA

BTIG analyst Mark Massaro has maintained a Buy rating on Natera (NASDAQ:NTRA) and increased the price target from $75 to $85.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 12:06 pm